share_log

Rodman & Renshaw Initiates Coverage On Trevi Therapeutics With Buy Rating, Announces Price Target of $7

Rodman & Renshaw Initiates Coverage On Trevi Therapeutics With Buy Rating, Announces Price Target of $7

Rodman & Renshaw發起對trevi therapeutics的買入評級,宣佈目標價爲7美元。
Benzinga ·  06/13 13:40

Rodman & Renshaw analyst Brandon Folkes initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Buy rating and announces Price Target of $7.

羅德曼和倫肖分析師布蘭登·福爾克斯開始對Trevi Therapeutics(納斯達克股票代碼:TRVI)進行報道,評級爲買入,並宣佈目標股價爲7美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論